Discover
e-ESO Podcasts
The Lines of Therapy After Progression on CDK4/6 Inhibitors Plus Endocrine Therapy to Overcome the Resistance in HR+/Her2 - Metastatic Breast Cancer Patients

The Lines of Therapy After Progression on CDK4/6 Inhibitors Plus Endocrine Therapy to Overcome the Resistance in HR+/Her2 - Metastatic Breast Cancer Patients
Update: 2024-12-12
Share
Description
Eman Aboelkheir, Alexandria University, Alexandria, Egypt
Comments
In Channel
00:00
00:00
x
0.5x
0.8x
1.0x
1.25x
1.5x
2.0x
3.0x
Sleep Timer
Off
End of Episode
5 Minutes
10 Minutes
15 Minutes
30 Minutes
45 Minutes
60 Minutes
120 Minutes





















